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AntioxidantAbstract 3-Hydroxy-3-methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors, referred to as
‘‘statins’’ have been extensively reported to possess lipid lowering effects by inhibiting the synthesis of
cholesterol by liver and thereby increasing hepatic cholesterol uptake and reducing circulating lipid
levels. Growing body of evidences have shown that apart from lipid lowering effects, statins possess
various pleiotropic effects that include improvement in endothelial dysfunction, increased expression
of endothelial nitric oxide synthase (eNOS), enhanced bioavailability of nitric oxide (NO), potent
antioxidant potential and anti-inﬂammatory properties. In relation to cardiovascular pathologies,
statins have been shown to inhibit atrial myocardial remodeling, prevent atrial ﬁbrillation, conserve
NOproduction in heart failure, reduce activity of smallG-proteins in cardiac hypertrophy and protect
the myocardium from lethal ischemia/reperfusion (I/R) injury. The mechanisms underlying the car-
dioprotective potential include phosphatidyl inositol (PI3)-kinase/Akt/eNOS pathway, subsequent
activation of ATP sensitive potassium (KATP) channels by NO resulting in improved myocardial
metabolism, release of endogenous adenosine by increasing the activity of adenosine forming enzyme
ecto-5V-nucleotidase, inhibition of reactive oxygen species (ROS) production, decrease in oxidative
stress and attenuation of apoptosis. The present review article demonstrates the pleiotropic effects
of statins beyond their lipid lowering effects. Moreover, the underlying mechanisms involved in
stain-induced cardioprotection have been delineated.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
S22 A. Rohilla et al.Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S22
2. Pravastatin and cardioprotection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S23
3. Atorvastatin and cardioprotection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S23
4. Simvastatin and cardioprotection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S24
5. Rosuvastatin and cardioprotection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S25
6. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S25
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S25Figure 1 Signaling pathways involved in statin-mediated car-
dioprotection. eNOS, endothelial nitric oxide synthase; ROS,
reactive oxygen species; TNF-a, tumor necrotic factor alpha; NF-
jB, nuclear factor kappa B; IL-6, interleukin-6; NO, nitric oxide.1. Introduction
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors known as statins are potent inhibitors of
cholesterol biosynthesis and exert beneﬁcial effects in the pri-
mary and secondary prevention of coronary artery disease
(Liao and Laufs, 2005). In addition, statins have been shown
to exert extrahepatic, cholesterol independent effects in animal
studies that have been referred to as pleiotropic effects that in-
clude direct effects on vascular tissue, heart, kidney, bone, and
glucose metabolism that are apparently independent of their
action on blood lipids (Palinski, 2001; Ferro, 2002; McFarlane
et al., 2002; Laufs and Bohm, 2005). These include effects on
the cardiovascular system, kidneys, bone, and glucose metab-
olism. A number of clinical trials have shown that statins sig-
niﬁcantly reduce cardiovascular morbidity and mortality.
Potential mechanisms that may mediate beneﬁcial cardiovas-
cular action of statins include modulation of endothelial func-
tion (Mital et al., 2000; Alvarez de Sotomayor et al., 2000;
Mehta et al., 2001), anti-inﬂammatory action (Egashira
et al., 2000; Jialal et al., 2001), antioxidant properties (Wagner
et al., 2000), plaque stabilization (Crisby et al., 2001), and ef-
fects on thrombosis (Rosenson and Tangney, 1998) and vascu-
logenesis (Vasa et al., 2001).
Statin is the generic sufﬁx used to classify the HMG-CoA
reductase inhibitors worldwide. The preﬁx is speciﬁc and iden-
tiﬁes the pharmaceutical company that manufactures and dis-
tributes the drug: for example, lovastatin, mevastatin,
pravastatin, atorvastatin, simvastatin, and rosuvastatin. Daii-
chi Sankyo in the year 1973 discovered the world’s ﬁrst statin
named mevastatin. Although mevastatin is not used in medical
therapy, it is often used as a starting compound to manufacture
other statins such as pravastatin, an active ingredient also
developed by Daiichi Sankyo. The cardioprotective potential
of statins has been conﬁrmed by a wide array of studies with re-
spect to cardiovascular pathologies in which statins have been
shown to inhibit atrial myocardial remodeling, prevent atrial
ﬁbrillation, conserve NO production in heart failure, reduce
the activity of small G-proteins in cardiac hypertrophy, con-
tribute to post-ischemic myocardial repair through mobiliza-
tion of endothelial progenitor cells and protect the
myocardium from lethal I/R injury (Dimmeler et al., 2001;
Laufs et al., 2002; Trochu et al., 2003; Porter et al., 2004a,b;
Kumagai et al., 2004). The mechanisms underlying these pro-
tective effects include improvement in vascular relaxation by
increasing eNOS expression and thereby enhancing NO release,
decreasing neutrophil inﬁltration by inhibiting ROS produc-
tion and attenuate apoptosis (Di Napoli et al., 2001; Wolfrum
et al., 2004). The accumulation of intracellular ROS up-
regulates the Akt pathway, which in turn enhances theaccumulation of intracellular ROS and ultimately induces
apoptotic cell death and secondary necrotic cell death
(Kawabata et al., 2001; Wolfrum et al., 2003; Verma et al.,
2004). Experimental data suggested that NO is an important
component of myocardial I/R injury and can modulate ROS
metabolism by reaction with free radicals such as superoxide
in the formation of peroxinitrite. Statins have been noted to
possess potent antioxidant effects through suppression of dis-
tinct oxidation pathways which include formation of myeloper-
oxidase-derived and NO-derived oxidants accounting for their
anti inﬂammatory and antioxidant actions. Moreover, the sta-
tin-induced cardioprotection has been noted to involve extra-
cellular regulated kinase (ERK1/2)/nuclear factor-kappa B
(NF-jB) pathway along with PI3-kinase/Akt/eNOS pathway
(Wolfrum et al., 2004; Verma et al., 2004). In addition, statins
has been reported to induce a signiﬁcant decrease in tumor
necrotic factor-alpha (TNF-a), interleukin-6 (IL-6) and mal-
ondialdehyde (MDA) along with a signiﬁcant increase of super-
oxide dismutase (SOD) activity that accounts for its
cardioprotective and antioxidant actions (Takemoto et al.,
2001; Bokoch and Diebold, 2002; Maack et al., 2003)
(Fig. 1). Furthermore, clinical studies have also demonstrated
the cardioprotective role of statins in patients undergoing car-
diopulmonary bypass surgery by showing signiﬁcant beneﬁcial
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cardioprotective markers (Mehra et al., 2002; Wainwright,
2005). The present review article reveals the pleiotropic effects
of statins along with the underlying mechanisms involved in
stain-induced cardioprotection.
2. Pravastatin and cardioprotection
Pravastatin, a member of the drug class known as statins,
chemically is (3R,5R)-3,5-dihydroxy-7-((1R,2S,6S,8R,8aR)-6-
hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-
hexahydronaphthalen-1-yl)-heptanoic acid (Fig. 2). It has been
noted that the pravastatin therapy improved the endothelium-
dependent coronary vasomotion that contributed in the
improvement of myocardial perfusion as well as regression
of coronary atherosclerosis. Treatment with pravastatin pre-
vented the reperfusion-induced ventricular tachycardia and
ventricular ﬁbrillation in rats that evidenced its beneﬁcial role
in decreasing cardiovascular mortality (Chen et al., 2003).
Moreover, pravastatin treatment has been noted to prevent
cardiovascular remodeling in the spontaneous diabetic rat
model by increasing the expression of cardiac eNOS and inhib-
iting the over expressions of ﬁbrogenic/proinﬂammatory cyto-
kines (Yu et al., 2004). Pravastatin treatment prevented
cardiomyocyte cell death following simulated hypoxia and
reoxygenation by increasing NO release, decreasing myocyte
endothelin-1 (ET-1) production and increasing Akt phosphor-
ylation that demonstrated the novel protective role of prava-
statin in human ventricular cardiomyocytes independent of
endothelial cells types (Verma et al., 2004; Favaro et al.,
2008). Statin therapy may restore ischemic hearts to full func-
tional integrity during cardioplegic arrest through a direct ef-
fect on cardiomyocyte survival showing its potential in
attenuating heart failure (Verma et al., 2004; Bezerra and
Mandarim-de-Lacerda, 2005; Reddy et al., 2005). Moreover,
pravastatin has been noted to exert antihypertropic effects by
activation of KATP channels resulting in the amelioration of
cardiomyocyte hypertrophy in rabbits (Lee et al., 2004). Prav-
astatin administration improved ﬂow-mediated dilatation
revealing its pleiotropic effects during the early phase of acute
coronary syndrome. In addition, the circulating lipid peroxida-
tion products in patients with unstable angina decreased signif-
icantly with pravastatin therapy (Cannon et al., 2004; Karatzis
et al., 2005; Ky et al., 2008). The antioxidant effect of prava-
statin was further conﬁrmed by the fact that pravastatin in
combination with pioglitazone modulated ANG II-mediated
oxidative stress, inhibiting mitogen-activated protein kinase
(MAPK) and NF-jB activation in mice (Chen and Mehta,
2006). Further, administration of pravastatin attenuated leftFigure 2 Chemical structure of pravastatin.ventricular hypertrophy by reducing the levels of oxidative
stress markers and matrix metalloproteinase activity in rat
heart (Ichihara et al., 2006; Abe et al., 2006). Moreover,
numerous experimental studies have reported that administra-
tion of pravastatin has been shown to hinder radical oxygen
species production by inhibiting protein kinase C-delta
(PKC-d) activation (Ceolotto et al., 2006; Kassan et al.,
2010). The cardioprotective and antioxidant effect of pravasta-
tin was further conﬁrmed by the fact that treatment with prav-
astatin showed prevention of impaired NO-dependent
vasodilation and NADPH oxidase-mediated-ROS generation
by blocking the down-regulation of Akt/eNOS pathways in
rats (Ohkawara et al., 2010). Furthermore, administration of
pravastatin showed cardioprotection in rats as assessed by bet-
ter recovery of cardiac function (improvement in heart rate,
left ventricular developed pressure, coronary ﬂow and coro-
nary resistance,) less release of biomarkers of cardiac injury
(lactate dehydrogenase, creatine kinase-MB and endothelin-
1) and attenuation of ventricular arrhythmias (ventricular
tachyarrhythmia and ventricular ﬁbrillation) (Li et al., 2010).
Chronic use of pravastatin after infarction resulted in en-
hanced connexin-43 quantity by attenuating mevalonate-
dependent ET-1 production through PKC-dependent pathway
conﬁrming its antiarrythmic effect in rats (Chen et al., 2010).
Additionally, pravastatin has been reported to signiﬁcantly re-
duce the cardiac AT-II levels and angiotensin converting en-
zyme 1 and 2 expressions normalizing the cardiac
sympathetic hyper-responsiveness in rats conﬁrming its potent
cardioprotective effect (Herring et al., 2010).
3. Atorvastatin and cardioprotection
Atorvastatin, another member of the drug class known as
statins, chemically is (3R,5R)-7-[2-(4-ﬂuorophenyl)-3-phenyl-4-
(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydro-
xyheptanoic acid (Fig. 3). It has been noted that atorvastatin
treatment produced endothelium-dependent vasodilation and
improved endothelial dysfunction in rats by decreasing oxida-
tive stress (Aviram et al., 1998; Perticone et al., 2000). Atorva-
statin showed protective effect in heart which is mediated by
an increase in eNOS expression and thereby increase in NO
bioavailability (Birnbaum et al., 2003). Administration with
atorvastatin signiﬁcantly reduced thiobarbituric acid reactive
oxygen substances (TBARS) levels and lipid peroxide concen-
trations as well as increased the reduced glutathione levels, the
oxidative stress markers, which further evidenced its antioxi-
dant action (Mahfouz and Kummerow, 2005; Ozacmak
et al., 2007). It has been widely accepted that myocardial injury
is associated with increased oxidative stress which involvesFigure 3 Chemical structure of atorvastatin.
Figure 4 Chemical structure of simvastatin.
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and cardiac free radical formation, normalized the expression
of the NADPH oxidase and showed anti-oxidative properties
along with enhancement of NO synthesis (Mahfouz and
Kummerow, 2005; Bolayirli et al., 2007). Moreover, adminis-
tration of isoproterenol produced severe myocardial damage
and oxidative stress in rats. Atorvastatin treatment reduced
myocardial infarction in rat hearts as assessed in terms of
improvement in serum parameters, ATPase activities and
reduction in oxidative stress. The lipid-independent anti-oxida-
tive and anti-inﬂammatory effects of atorvastatin involve
ERK1/2/NF-jB-pathway that is noted to afford cardioprotec-
tion (Riad et al., 2007). Moreover, the decrease in oxidative
stress in subjects with metabolic syndrome was also noted with
atorvastatin treatment (Singh et al., 2008). Atorvastatin has
been reported to induce a signiﬁcant decrease in TNF-a,
IL-6 and MDA along with a signiﬁcant increase of SOD activ-
ity that accounts for its cardioprotective and antioxidant
action (Castro et al., 2008). High-fat diets signiﬁcantly in-
creased the C-reactive protein (CRP) levels and oxidative stress
and compromised mitochondrial response to ischemia that was
found to be reversed by atorvastatin treatment in a high-fat
diet rat model which provide a superior control of cardiovas-
cular risk markers in diabetic and hyperlipidemic subjects
(Matafome et al., 2008). Moreover, atorvastatin has been
noted to reduce systemic oxidative stress by direct inhibition
of protein oxidation and oxidative DNA damage (Aydin
et al., 2009). Additionally, atorvastatin treatment reduced elec-
trophysiological alteration induced by I/R in isolated rat
hearts as assessed in terms of prolonging the effective refrac-
tory period mediated by activation of NO pathway ultimately
enhancing the myocardial electrophysiological stability (Xu
et al., 2010a,b). Furthermore, recent studies have demon-
strated that atorvastatin inhibited homocysteine-induced
NADPH oxidase activation, ROS accumulation and apoptosis
through p38MAPK dependent mechanisms that contribute to
atorvastatin-mediated card protective effects (Bao et al., 2010).
An interesting study conﬁrmed the cardioprotective effect of
atorvastatin as assessed by restoration of the infarct size-limit-
ing and contractile dysfunction-reducing effect of ischemic
postconditioning in rat hearts, the mechanism of which in-
volved increased phosphorylation of Akt and eNOS (Ying
et al., 2010). Clinically, treatment of atorvastatin inhibited
oxidative stress by adiponectin-mediated NADPH oxidase
down-regulation in hypercholesterolemic patients that further
evidenced atorvastatin’s antioxidant effect. The cardioprotec-
tive potential of atorvastatin was further conﬁrmed by the fact
that atorvastatin treatment reversed hypertension-induced car-
diac remodeling in rats by down-regulating PKD and myocyte
enhancer factor which may serve as a novel therapeutic target
for atorvastatin in treating hypertensive patients (Bacova
et al., 2010; Geng et al., 2010).
4. Simvastatin and cardioprotection
Simvastatin, third member of the statins class, chemically
is (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-
yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydrona phthalen-1-
yl-2,2-dimethylbutanoate (Fig. 4). Simvastatin is a potent
cardioprotective agent that inhibit leukocyte endothelial cell
interactions and preserve cardiac contractile function andcoronary perfusion after myocardial I/R and this effect is med-
iated by enhanced endothelial release of NO (Lefer et al., 1999;
Di Napoli et al., 2001). The cardioprotective effect of simva-
statin in a model of I/R in the Langendorff rat heart has been
reported as assessed in terms of increased eNOS expression
and thereby increased NO bioavailability (Di Napoli et al.,
2001). The leukocytic and aortic productions of ROS along
with protein and lipid oxidation products such as TBARS were
prevented in an experimental model by simvastatin conﬁrming
its antioxidant effect (Delbosc et al., 2002). It ahs been re-
ported that simvastatin improved the erythrocyte ﬁlterability
in patients with familial hypercholesterolemia evidencing its
potential cardioprotective role in clinical patients (Koter
et al., 2003). In addition, experimental studies have shown that
administration of simvastatin attenuated the oxidative stress
and afforded cardioprotection by decreasing MDA levels
and increasing the SOD and NO levels (Bayorh et al., 2005;
Yin et al., 2007). Further, treatment with simvastatin was
noted to be effective in reducing the oxidative stress and infarc-
tion volume that was responsible for ameliorating ischemic
damage in rats. It ahs been reported that simvastatin pretreat-
ment signiﬁcantly reduced reperfusion arrhythmias occurring
after regional ischemia in an open chest diabetic-hypercholes-
terolemic rat model (Adameova´ et al., 2006). Simvastatin re-
duced the activity of NADPH-CoQ reductase, an enzyme
required in generation of free radicals that further evidenced
its potent role as an antioxidant (Kettawan et al., 2007). Clin-
ical studies have also suggested the cardioprotective role of
simvastatin in patients undergoing cardiopulmonary bypass
surgery by showing signiﬁcant beneﬁcial effects by decreasing
lipid peroxidation (Coccia et al., 2007). Moreover, the treat-
ment with simvastatin has been noted to possess antioxidant
effect in diabetic-hypercholesterolemic rats (Kuzelova´ et al.,
2008). Furthermore, simvastatin treatment signiﬁcantly im-
proved endothelial function and reduced oxidative stress that
evidenced its antioxidant action in order to afford cardiopro-
tection (Tong et al., 2009). Decrease in postischemic recovery
of left ventricular developed pressure, increase in ventricular
ﬁbrillation, lengthening the duration of ventricular tachycardia
and increase in myocardial infarct size are the markers of myo-
cardial damage that was found to be reversed by simvastatin
treatment that conﬁrmed its pleiotropic in both healthy and
diseased individuals (Adameova et al., 2009). Additionally,
simvastatin has been recently reported to signiﬁcantly reduce
total cholesterol, triglycerides, low density lipoproteins, conju-
gated diene, total peroxide, and malondialdehyde levels that
further evidenced its potential role as antioxidant and cardio-
protective agent (Kumar, 2010).
Figure 5 Chemical structure of rosuvastatin.
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Rosuvastatin, the latest member of statins class, chemically is
(3R,5S,6E)-7-[4-(4-ﬂuorophenyl)-2-(N002Dmethylmethanesulfo-
namido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-
enoic acid (Fig. 5). It has been reported that treatment with
rosuvastatin increased vascular endothelial NO production
and attenuated myocardial necrosis following I/R in mice evi-
dencing its potential cardioprotective effect (Jones et al., 2002).
Moreover, rosuvastatin given 18 h before I/R has signiﬁcantly
improved left ventricular developed pressure and the maximal
rate of development of left ventricular developed pressure in a
rat model of I/R which provide evidence that rosuvastatin sig-
niﬁcantly attenuated cardiac contractile dysfunction in isolated
perfused rat hearts (Ikeda et al., 2003). Administration with
rosuvastatin has been noted to reduce arterial pressure in ge-
netic hypertension and improve systemic and regional hemo-
dynamics in hypertensive rat hearts conﬁrming its potent
cardioprotective role (Susic et al., 2003; Neto-Ferreira et al.,
2011). In addition, it has been demonstrated that rosuvastatin
exerted potent antioxidative effects which were capable of pre-
venting DNA damage in vivo by involving the induction of the
expression of antioxidant defense enzymes (Grosser et al.,
2004; Schupp et al., 2008). Further, chronic treatment with
rosuvastatin before ischemia reduced I/R injury in rat hearts
and prevented coronary endothelial cell and cardiomyocyte
damage by NO-dependent mechanisms (Di Napoli et al.,
2005). Rosuvastatin signiﬁcantly reduced infarct size in mice
hearts after 60 min of I/R suggesting its potential as a cardio-
protective agent as assessed by reduction in neutrophil inﬁltra-
tion and increasing the expression of eNOS and thereby
increasing NO production (Weinberg et al., 2005). Addition-
ally, rosuvastatin treatment has been reported to normalize
the endothelial function and reduce the platelet activation in
diabetic rats which may contribute to the reduction of cardio-
vascular events by statins in diabetic patients (Scha¨fer et al.,
2007). The normalization of ROS production and platelet
aggregation in a hamster model by rosuvastatin treatment
has further conﬁrmed its potential as a vasculoprotective and
cardioprotective agent (Miersch et al., 2007; Almeid et al.,
2009). The elevations of left ventricular wet weight, myocardial
extracellular matrix content, diastolic stiffness, and alterations
in systolic and diastolic function are the markers of heart fail-
ure that were noted to be inhibited by chronic rosuvastatin
treatment in rat hearts (Loch et al., 2009). Furthermore, rosu-
vastatin treatment showed a protective role in rat model of left
ventricular hypertrophy as assessed in terms of attenuation of
myocardial ﬁbrosis and left ventricular stiffness (Chang et al.,
2009). Rosuvastatin treatment was noted to reduce plasma
concentrations of total cholesterol, low density lipoproteinsand triglycerides, urine and plasma oxidative stress markers
and plasma CRP in hypercholesterolemic patients that further
evidenced its antioxidant effect (Yoshino et al., 2009; Koksal
et al., 2010). It has been recently reported that rosuvastatin
in combination with standard heart failure therapy results in
a signiﬁcant additional improvement in heart failure and car-
diac remodeling in rats conﬁrming its potent cardioprotective
effect (Go´mez-Garre et al., 2010; Ying et al., 2010). In addi-
tion, short-term treatment with rosuvastatin signiﬁcantly in-
creased the number of circulating endothelial progenitor cells
in patients with heart failure that further conﬁrmed its antiox-
idant and cardioprotective effect providing further insights
into its role in these individuals (Tousoulis et al., 2011).
6. Conclusion
Accumulating evidence indicates that statin therapy favorably
inﬂuences a number of diverse clinical events through both ef-
fects related to lowering of cholesterol levels and effects inde-
pendent of the lowering of cholesterol levels. The latter
effects are referred to as pleiotropic. The pleiotropic effects
of the statins improve vascular relaxation, promote new vessel
formation, inhibit platelet aggregation and reducing vascular
inﬂammation. It is noteworthy that the pleiotropic properties
of the statins have been beneﬁcial in a variety of diseases that
involve a number of organs and organ systems. By enhancing
eNOS expression and thereby increasing NO bioavailability,
reducing oxidative stress and proinﬂammatory cytokine pro-
duction and preventing ROS production and apoptosis, the
HMG-CoA reductase inhibitors may prove to be useful agents
in treating patients with cardiovascular diseases. The ﬁndings
of this study, therefore, may have important clinical implica-
tions since cardiovascular diseases are a major cause of mor-
bidity and mortality worldwide. Moreover, the observations
that acute exposure to statins may also afford cardioprotection
imply their potential use in situations of controlled, deliberate
myocardial I/R, such as coronary angioplasty, coronary artery
by-pass grafting and cardiac transplantation that would open
new doors for the treatment strategies of such patients. The
beneﬁcial role of statins in the experimental setting of myocar-
dial I/R injury would surely open new gates in the treatment of
patients presented with coronary heart disease. The clinical rel-
evance of these effects is beginning to be recognized and fur-
ther studies would be able to answer such questions in the
near future.
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